The latest price target for Heron Therapeutics (NASDAQ:HRTX) was reported by HC Wainwright & Co. on January 9, 2026. The analyst firm set a price target for $6.00 expecting HRTX to rise to within 12 months (a possible 319.58% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Heron Therapeutics (NASDAQ:HRTX) was provided by HC Wainwright & Co., and Heron Therapeutics reiterated their buy rating.

There is no last upgrade for Heron Therapeutics

There is no last downgrade for Heron Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Heron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Heron Therapeutics was filed on January 9, 2026 so you should expect the next rating to be made available sometime around January 9, 2027.

While ratings are subjective and will change, the latest Heron Therapeutics (HRTX) rating was a reiterated with a price target of $6.00 to $6.00. The current price Heron Therapeutics (HRTX) is trading at is $1.43, which is out of the analyst’s predicted range.